New approach to neonatal sepsis in developing nations could save thousands of lives

October 22, 2018, American Society for Microbiology

Sepsis is a major cause of preventable death among newborn children in tropical countries. Now the antibiotic ceftriaxone, which has been available only as an injectable, can be administered through rectal delivery. This method could annually save the lives of several hundred thousand newborns with sepsis. The research is published in Antimicrobial Agents and Chemotherapy, a journal of the American Society for Microbiology.

Sepsis is an overwhelming immune response to infection that can lead to tissue damage, organ failure, and death.

There is a need for a rectal formulation because in parts of the world where these deaths are common, resources are limited, sterile hospital settings suitable for injection therapy are few and far between—"... often hours or days away," and prompt treatment is necessary to save lives, according to the report.

"A rectal antibiotic could reduce mortality by shortening lethal delays in treating critically ill newborns," said corresponding author Tina Kauss, Ph.D., PharmD, Assistant Professor in Pharmaceutical Technology and Biopharmacy, the University of Bordeaux, France.

The research, a collaboration between Hoffman la Roche and University scientists, summarizes and builds upon work performed in the early 1980s at the drug company, Hoffmann la Roche, said Dr. Kauss. Roche had evaluated injectable and rectal formulations of ceftriaxone, but registered only the injectable product. Their human rectal data remained unpublished.

"Rectal delivery of drugs for severely ill patients has been shown to be life-saving for malaria and could achieve the same objective with neonatal sepsis, a treatable infection," said Dr. Kauss. Rectal delivery enables treatment even during critical illnesses where neonates are undergoing convulsions, or are unconscious, in shock, or unable to feed.

The collaboration with Hoffmann la Roche boosted the likelihood of success and shortened timelines, as Roche had invested extensively in the chemistry and pharmaceutical development of rectal formulations of ceftriaxone.

"Their data showed that ceftriaxone always needed an absorption enhancer in the formulation to increase rectal , and they tested more than 30 absorption enhancers for bioavailability, alone, or in combination with other enhancers in different formulations," said Dr. Kauss.

Without absorption enhancement, bioavailability—the amount of an agent that reaches its target—hovered in the mid-single digits. With certain absorption enhancers in the formulation, bioavailability reached 50 percent in rabbits, justifying further work in primates and humans, according to the report. In baboons, it reached 69 percent. Additionally, bioavailability via the rectum in week-old infants is double that of adults, therefore requiring fewer doses in infants.

Following their review of the Hoffman data, the investigators developed new formulations. Only those few that proved stable under tropical conditions were developed further, said Dr. Kauss. "Since Roche provided the full information on a fatty-suppository formulation which they had used for studies of bioavailability in humans, we replicated this suppository and assessed its bioavailability in rabbits," she said. "The new rabbit data therefore provides a reference or benchmark against which one can measure bioavailability of new rectal formulations, in order to predict human bioavailability."

Ceftriaxone has multiple advantages over other antibiotics. Sepsis has multiple causal pathogens, but ceftriaxone is broad spectrum. It has a good safety record in newborns, good central nervous system penetration, and "a single daily dose is possible because [ceftriaxone] has much slower elimination than other third generation cephalosporins, penicillins, or carbapenems," according to the report.

"We are now producing a clinical batch of the best formulations we developed, for human bioavailability assessment," said Dr. Kauss.

Explore further: Acetaminophen can reduce recurrence of febrile seizures

Related Stories

Acetaminophen can reduce recurrence of febrile seizures

October 9, 2018
(HealthDay)—Acetaminophen can reduce the risk for febrile seizure (FS) recurrence during the same fever episode among infants and children, according to a study published online Oct. 8 in Pediatrics.

Drug-resistance of gonorrhea in the EU: persistent but stable

August 30, 2018
Neisseria gonorrhoea continues to show high levels of resistance to azithromycin across the European Union and European Economic Area, according to the 2016 results of the European Gonococcal Antimicrobial Surveillance Programme ...

Enhancing absorption and bioavailability of curcumin and turmeric

August 13, 2015
Few natural products have demonstrated the range of protective and therapeutic promise as have turmeric and its principal bioactive components, the curcuminoids. Success in translating this potential into tangible benefits ...

Younger patients don't attain survival benefit from current rectal cancer treatment recommendations

July 9, 2018
A new study reveals that individuals younger than 50 years of age who are diagnosed with rectal cancer do not experience an overall survival benefit from currently recommended treatments. Specifically, the addition of chemotherapy ...

Recommended for you

Infants born to obese mothers risk developing liver disease, obesity

November 16, 2018
Infant gut microbes altered by their mother's obesity can cause inflammation and other major changes within the baby, increasing the risk of obesity and non-alcoholic fatty liver disease later in life, according to researchers ...

New study shows NKT cell subsets play a large role in the advancement of NAFLD

November 16, 2018
Since 2015 it has been known that the gut microbiota could have a direct impact on nonalcoholic fatty liver disease (NAFLD), which affects up to 12% of adults and is a leading cause of chronic liver disease. In the November ...

Antibiotic prescribing influenced by team dynamics within hospitals

November 15, 2018
Antibiotic prescribing by doctors is influenced by team dynamics and cultures within hospitals.

Discovery suggests new route to fight infection, disease

November 14, 2018
New research reveals how a single protein interferes with the immune system when exposed to the bacterium that causes Legionnaires' disease, findings that could have broad implications for development of medicines to fight ...

Zika may hijack mother-fetus immunity route

November 14, 2018
To cross the placenta, Zika virus may hijack the route by which acquired immunity is transferred from mother to fetus, new research suggests.

New research aims to help improve uptake of hepatitis C testing

November 14, 2018
New research published in Scientific Reports shows persisting fears about HIV infection may impact testing uptake for the hepatitis C Virus (HCV).


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.